Literature DB >> 14614207

Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.

Katsuyasu Ishikawa1, Takashi Ohba, Nobuyuki Tanaka, Munir Iqbal, Yoshinori Okamura, Hitoshi Okamura.   

Abstract

Overproduction of vascular endothelial growth factor (VEGF) following human chorionic gonadotropin (hCG) stimulation has been implicated as one of the causative factors in the development of ovarian hyperstimulation syndrome (OHSS). The objective of this study was to clarify the action of hCG and progesterone, one of the possible factors for OHSS, on VEGF production and gene expression using OHSS-model rats. A total of 40 immature female Wistar rats were stimulated with 10 IU of equine chorionic gonadotropin for four consecutive days from the 22nd to 25th day of life followed by subcutaneous injection of 30 IU of hCG on the 26th day of life. RU486 and progesterone were injected 24 h after the hCG injection. Tissues and blood samples were collected on the 28th day. hCG elicited VEGF production in the OHSS-model rat ovaries. Ovarian weights of the OHSS model rats were significantly increased through day 26 by the ovarian stimulation with single dose of 30 IU hCG. Addition of anti-progesterone RU486, which reduced the ovarian enlargement, attenuated VEGF production dose dependently whereas the VEGF gene expression was stable. In the lung and liver, neither hCG nor RU486 affected VEGF production and gene expression. These results suggested that progesterone regulates VEGF production at the post-transcriptional level in a tissue specific manner in the hyperstimulated ovary.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614207     DOI: 10.1507/endocrj.50.515

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Expression of vascular endothelial growth factor A during ligand-induced down-regulation of luteinizing hormone receptor in the ovary.

Authors:  M Harada; H Peegel; K M J Menon
Journal:  Mol Cell Endocrinol       Date:  2010-07-07       Impact factor: 4.102

2.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

3.  Association between LH receptor regulation and ovarian hyperstimulation syndrome in a rodent model.

Authors:  Cuihong Zheng; Thippeswamy Gulappa; Bindu Menon; K M J Menon
Journal:  Reproduction       Date:  2020-08       Impact factor: 3.923

4.  Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation.

Authors:  Annunziata Mauro; Alessandra Martelli; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Oriana Di Giacinto; Mauro Mattioli; Barbara Barboni
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

5.  Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome.

Authors:  You Jee Jang; Hee Kyung Kim; Bum Chae Choi; Sang Jin Song; Jae Il Park; Sang Young Chun; Moon Kyoung Cho
Journal:  Reprod Biol Endocrinol       Date:  2021-04-01       Impact factor: 5.211

6.  Coenzyme Q10 improves ovarian histology and attenuates the expression of angiogenesis-associated proteins in the ovary of rats with experimental hyperstimulation syndrome.

Authors:  Zahra Darabi; Zahra Basir; Mohammad Reza Tabandeh; Zohreh Ghotbeddin
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

7.  Effects of P4 Antagonist RU486 on VEGF and Its Receptors' Signaling during the In Vivo Transition from the Preovulatory to Periovulatory Phase of Ovarian Follicles.

Authors:  Annunziata Mauro; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Alessandra Martelli; Delia Nardinocchi; Oriana Di Giacinto; Maura Turriani; Barbara Barboni
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.